Navigation Links
Arete Therapeutics Bolsters Management Team
Date:10/29/2008

Appoints Euan MacIntyre, Ph.D. as Senior Vice President of Drug Discovery

HAYWARD, Calif., Oct. 29 /PRNewswire/ -- Arete Therapeutics Inc., a privately-held biopharmaceutical company developing first-in-class soluble epoxide hydrolase (s-EH) inhibitors, today named D. Euan MacIntyre, Ph.D., to the newly-created position of Senior Vice President, Drug Discovery. Dr. MacIntyre brings over 20 years of pharmaceutical drug discovery and development leadership to Arete Therapeutics.

"We are extremely pleased to welcome Euan as a member of our executive management team, as his broad drug discovery expertise and disease-specific knowledge will bolster our ability to develop effective s-EH inhibitors," said James H. Sabry, M.D., Ph.D., President and Chief Executive Officer of Arete Therapeutics. "Given his scientific accomplishments and exceptional track record in advancing discovery programs through clinical development, I am confident Euan will provide invaluable insights and leadership as we finalize our plans to initiate a phase II study of AR9281 to treat metabolic syndrome and build out our expertise in this unique area of biology."

Dr. MacIntyre comes to Arete after more than 22 years with Merck Research Laboratories, where he held positions of escalating importance, most recently as Vice President of Pharmacology. Under his leadership, Dr. MacIntyre's team identified and validated several compounds now commercially available or in clinical trials for a variety of diseases and conditions including emesis, diabetes, obesity, hypertension, hyperlipidemia, pain, urinary incontinence and immuno-inflammatory disorders. In addition to his experience in discovery and development, Dr. MacIntyre evaluated numerous in-licensing candidates and served as a member of several joint research committees for Merck's joint ventures and collaborations. Dr. MacIntyre received his Ph.D. in pharmacology and experimental pathology from the University of Cambridge. H
'/>"/>

SOURCE Arete Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Arete Therapeutics Names James Sabry, M.D., Ph.D., President and Chief Executive Officer
2. Sirnaomics Receives SBIR Grant from NCI For Its Multi-Targeted Cancer siRNA Therapeutics
3. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
4. Nile Therapeutics to Present at the 7th Annual BIO Investor Forum
5. Nektar Therapeutics to Webcast R&D Day on November 12th
6. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
7. Sir Richard Sykes Joins BioCeramic Therapeutics as Chairman
8. Leading Heart Specialist Joins Duska Therapeutics as Scientific Consultant
9. CV Therapeutics to Announce 2008 Third Quarter Financial Results on Thursday, November 6, 2008
10. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
11. United Therapeutics to Announce Third Quarter 2008 Financial Results Before Market Open on Thursday, October 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Boston, MA (PRWEB) September 30, 2014 On ... Director James Sherley in anticipation of a session that ... -organized “Predictive Toxicology Summit,” scheduled for February 17-18, 2015 in ... September 15, Pharma IQ asked Dr. Sherley to respond to ... stem cell toxicity, challenges to evaluating stem cell toxicity, and ...
(Date:9/30/2014)... 30, 2014 Back in the 1970’s, many ... feet. per employee, which included space for circulation and file ... Jeff Howell, partner at Nidea Corporate Real Estate / ... “By the year 2000, however, 250 square feet per ... number come down to 175 to 225 square feet, and ...
(Date:9/29/2014)... diagnostics today, with imaging techniques like MRI (magnetic ... (nuclear magnetic resonance) increasing steeply over the last ... and quality still limit these techniques because of ... hyperpolarization, which involves injecting the patient with substances ... distribution and fate of specific molecules in the ...
(Date:9/29/2014)... Research and Markets  has announced the addition of ... End-User , Application - Global Forecast to 2019" ... oligonucleotide synthesis market is expected to reach $1,712.1 million ... a CAGR of 9.8% from 2014 to 2019. The ... of products and services, applications, end users, and geography. ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 2Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 3Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 4ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 3A safer approach for diagnostic medical imaging 2A safer approach for diagnostic medical imaging 3Oligonucleotide Synthesis (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) Market - Global Forecast to 2019 2Oligonucleotide Synthesis (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) Market - Global Forecast to 2019 3
... NORTH VANCOUVER, BC, July 23 /PRNewswire-FirstCall/ - Chromos ... that the,securities commissions or similar regulatory authorities in ... Quebec have revoked the,cease trade orders against the ... are currently no cease trade orders outstanding against ...
... Duska Therapeutics,Inc. (OTC Bulletin Board: DSKA) ("Duska") announced ... of a proposed Phase 3 clinical study for,its ... Drug Administration,s (the,"FDA") Division of Cardiovascular and Renal ... FDA, including a face-to-face,meeting held on April 16, ...
... 23 Tengion Inc., a clinical,stage biotechnology company focused ... it has appointed Mark Stejbach as Vice,President, Marketing and ... marketing, sales, finance, and managed care experience from,both Merck ... very pleased to welcome Mark to the Tengion executive ...
Cached Biology Technology:Chromos Announces Full Revocation of Cease Trade Orders 2Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment 2Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment 3Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment 4Tengion Appoints Mark Stejbach Vice President of Marketing & Commercial Planning 2
(Date:9/30/2014)... Ludwig-Maximilians-Universitaet (LMU) in Munich report that a new ... sensitive to chemotherapeutic drugs. They have also pinpointed ... target for anti-tumor agents. , Researchers led ... Sieber of the Technische Universitt Mnchen have identified ... new weapon in the fight against malignant tumors. ...
(Date:9/30/2014)... Sept. 30, 2014  Spectra Automation, a ... the biotech and power generation industries, announced ... Bioprocess Manager, an easy-to-use and cost-effective data ... bioprocess development laboratories. Most ... and analyzer systems. Accessing and consolidating data ...
(Date:9/29/2014)... called Clostridium ramosum , coupled with a high-fat diet, ... this week in mBio , the online open-access journal ... team from the German Institute of Human Nutrition Potsdam-Rehbruecke in ... C. ramosum gained weight when fed a high-fat diet. ... less obese even when consuming a high-fat diet, and mice ...
Breaking Biology News(10 mins):Cancer therapy: Driving cancer cells to suicide 2Spectra Automation Introduces RECONN Bioprocess Manager 2Gut bacteria promote obesity in mice 2
... Thanks to laws of elementary electrostatics, we can easily ... and therefore predict their movements. Submerge those particles ... the calculation grows more complex. The charged particles, movements ... or otherwise alter the particles, paths. In this environment ...
... Kevlar and other synthetic fabrics: Step aside. If new ... blouses and other garments made from fibers modeled after ... called the hagfish. The study appears in ACS, journal ... supervisor Douglas S. Fudge and colleagues explain that petroleum ...
... Mainz, Germany and the renowned School of Medicine at ... This strategic partnership promises to provide an innovative stimulus ... University Medical Center. The resulting regular exchange will benefit ... "Our aim is to arrive at a better ...
Cached Biology News:Outside a vacuum: Model predicts movement of charged particles in complex media 2Mainz University Medical Center agrees partnership with Yale University 2
... patented technology, the Lone Wolf valve has ... Open proportional valve available on the market. ... repeatable high-speed performance, and ensures maximum accuracy., ... Enhances system control and patient comfort. , ...
... is the smallest electronic pressure controller ... mm. Parker configured this unit specifically for ... markets. Used in carrier gas flow control, ... dispensing, and hydro-dynamic focusing, the OEM-EPC offers ...
... The VSO LF (Low Flow) offers the same ... control for applications where control is critical or ... solenoid-operated valve automates the flow of gas in ... either DC current or pulse width modulation; closed ...
...
Biology Products: